¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood group specific substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • blood dyscrasia
    Ç÷¾×º´
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • blood film
    Ç÷¾×Æì¹Ù¸¥Ç¥º», Ç÷¾×µµ¸»
  • blood flow
    1. Ç÷·ù 2. Ç÷·ù·®
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    1. Ç÷·ù·® 2. Ç÷·ù¼Óµµ
  • blood fluke
    ÁÖÇ÷ÈíÃæ
  • blood gas
    Ç÷¾×°¡½º
  • blood gas apparatus
    Ç÷¾×°¡½ººÐ¼®ÀåÄ¡
  • blood gas solubility coefficient
    Ç÷¾×°¡½º¿ëÇØ°è¼ö
  • blood glucose
    Ç÷´ç
  • blood glucose monitoring
    Ç÷´ç°¨½Ã
  • blood grouping
    Ç÷¾×Çü°Ë»ç
  • blood line
    Ç÷Á·°è, Ç÷Åë
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • osteoid substance
    Dz»À¹°Áú
  • oxytocic substance
    ÀڱüöÃ๰Áú
  • paramagnetic substance
    »óÀÚ¼º¹°Áú
  • perforated substance
    °üÅëÁú
  • periaqueductal gray substance
    ¼öµµ°üÁÖÀ§È¸»öÁú
  • postacrosomal substance
    ÷´ÜüµÚ¹°Áú
  • pressor substance
    Ç÷¾Ð»ó½Â¹°Áú
  • pyrogenic substance
    ¹ß¿­¹°Áú
  • radioactive substance
    ¹æ»ç¼±¹°Áú
  • radiomimetic substance
    ¹æ»ç¼±À¯»çÀÛ¿ë¹°Áú
  • reaction substance
    ¹ÝÀÀ¹°Áú
  • receptive substance
    ¼ö¿ë¹°Áú
  • reducing substance
    ȯ¿ø¹°Áú
  • released substance
    ¹æÃâ¹°Áú
  • reserve substance
    ÀúÀå¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
  • group hospital
    º´¿øÁ¶ÇÕ(ËÓËô̡̰).
  • group incompatibility
    Ç÷¾×±ººÎÀûÇÕ(úìäûÏØ ÝÕîêùê).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • erythrocyte sensitizing substance =ESS
    ÀûÇ÷±¸°¨ÀÛ¹°Áú(¡­ÊïíÂÚªòõ).
  • estrogenic substance conjugated
    ¸®°áÇÕ¿¡½ºÆ®·Î°Õ¹°Áú.
  • exophthalmos-producing substance
    ¾È±¸µ¹ÃâÀ¯¹ß¹°Áú.
  • ferromagnetic substance
    °­ÀÚ¼ºÃ¼.
  • fibrinoid substance
    ¼¶À¯¼Ò¼º¹°Áú
  • fundamental substance
    ¹«ÇüÁú
  • gelatinous substance
    ¾ÆaÁú, a¾çÁú(ÎïåÆòõ).
  • gelatinous substance
    ¾Æ±³Áú
  • gray substance
    ȸ»öÁú.
  • ground substance
    ±âÀú¹°Áú(Ðñî¼Úªòõ), ±âÁú(Ðñòõ).
  • heparinoid substance
    ÇìÆÄ¸°¾ç¹°Áú.
  • heterogeneous substance
    ºÒ±ÕÁúü.
  • horny substance
    °¢Áú(ÊÇòõ).
  • insulin-like activity substance
    Àν¶¸°¾çȰ¼º¹°Áú.
  • intercellular cement substance
    ¼¼Æ÷°£°áÇÕ¹°Áú(¡­Ì¿ùêÚªòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
SRS-A Slow Reacting Substance of Anaphylaxis
ADS acute death syndrome; acute diarrheal syndrome; Alcohol Dependence Scale; alternative delivery syste...
ALS acute lateral sclerosis; advanced life support; afferent loop syndrome; amyotrophic lateral sclerosi...
AMS ablepharon-microstomia syndrome; acute mountain sickness; adenosylmethionine synthetase; aggravated ...
ams amount of a substance
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
SAS surface active substance
A.S.I. Active Specific Immunotherapy
ASA Allele Specific Amplification
ASO Allele specific oligonucleotide
AS-PCR Allele specific polymerase chain reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood-tinged
    Ç÷¾×ÀÌ ¾à°£ ¼¯ÀÎ
  • bone-marrow blood transfusion
    °ñ¼ö ¼öÇ÷
    °æ°ñ°ú Èä°ñÀÇ °ñ¼ö¿¡ Ç÷¾×À» ÁÖÀÔÇÏ´Â ¼öÇ÷ÀÇ º¯¹ý. Ç×»ó ¾²´Â Á¤¸Æ ³» ¼öÇ÷·Î´Â °¨¼ö¼ºÀÌ Áö³ªÄ¡°Ô °­Çϰųª ¸öÀÌ ºñ¸¸ÇÏ¿© Á¤¸ÆÀ» ã±â ¾î·Á¿î ȯÀÚ ¶Ç´Â À¯¾Æ¸¦ ´ë»óÀ¸·Î ÇÒ °æ¿ì ÀÌ ¹æ¹ýÀ¸·Î ¼öÇ÷ÇÒ ¶§°¡ ÀÖ´Ù. ¶Ç ¹éÇ÷º´À̳ª Àç»ýºÒ·®¼º ºóÇ÷ ȯÀÚ¿¡°Ô´Â ÀÌ ¹æ¹ýÀÌ Á¤¸Æ ¼öÇ÷º¸´Ù ¶Ù¾î³­ È¿°ú°¡ ÀÖ´Ù´Â °ßÇØµµ ÀÖ´Ù. ¹æ¹ýÀº °ñ¼ö õÀÚ¸¦ ÇÏ¿© Á¡Àû ÀåÄ¡ ¶Ç´Â ´ëÇü ÁÖ»ç±â·Î äÇ÷ÇÑ Ç÷¾×À» °ñ¼ö ³»¿¡ ÁÖÀÔÇÑ´Ù. ´Ù·® ¼öÇ÷ÀÌ °¡´ÉÇÏÁö¸¸, ±¹ºÎ ÇÇºÎ¿Í °ñ¸·¿¡ ±¹¼Ò¸¶Ã븦 ÇØ¾ß ÇÒ Çʿ䰡 ÀÖ´Ù. ±×¸®°í Á¤¸Æ ¼öÇ÷º¸´Ù ½Ã°£ÀÌ °É¸®°í ¼¼½ÉÇÑ ÁÖÀǰ¡ ÇÊ¿äÇϸç, ȯÀÚ¿¡°Ô °íÅëÀ» Áְųª, ³Ê¹« »¡¸® ÁÖÀÔÇÏ¸é ±¹¼Ò¿¡ ÅëÁõÀ» ÁÖ´Â µîÀÇ °áÁ¡ÀÌ ÀÖ´Ù.
  • circulating blood volume
    ¼øÈ¯ Ç÷¾×·®
  • collection of blood sample
    äÇ÷
  • complete blood count
    ÀüÇ÷ °Ë»ç, ÀüÇ÷±¸ °è»ê
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • dark blood
    £Àº »öÀÇ Ç÷¾×
  • Diego blood type
    µð¿¡°í½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. 1954³â º£³×¼ö¿¤¶óÀÇ µð¿¡°í°¡¿¡¼­ ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ ȯÀÚÀÇ ¾î¸Ó´Ï Ç÷û¿¡¼­ Ç×ü°¡, ¾Æ¹öÁö¿¡°Ô¼­´Â Ç׿øÀÌ ¹ß°ßµÇ¾ú´Ù. Di Ç×ü¿¡ ´ëÇØ ÀûÇ÷±¸°¡ ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀ» Di
  • disorder of blood platelet
    Ç÷¼ÒÆÇ Àå¾Ö
  • Dombrock blood type
    µ¼ºê·Ï½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. »ç¶÷ÀÇ Ç÷±¸ °¡¿îµ¥ Ç×Do Ç×ü¿Í ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Do
  • effective blood volume
    À¯È¿ Ç÷¾×·®
  • electromagnetic blood flowmeter
    ÀüÀÚ±â Ç÷·ù ÃøÁ¤±â
  • fasting blood sugar level
    °øº¹ ½Ã Ç÷´çÄ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
specific urethritis An obsolete term for gonorrhoea.
(05 Mar 2000)
N(2),N(2)-dimethylguanosine-specific tRNA methyltransferase <enzyme> Responsible for the modification of both mitochondrial and cytoplasmic trnas
Registry number: EC 2.1.1.-
Synonym: dmg trna methyltransferase
(26 Jun 1999)
sporulation-specific cell wall hydrolase <enzyme> From bacillus subtilis; 255-amino acid protein mw 27.146 kD; hydrolyzes both vegetative cell walls and spore peptidoglycan genbank d14666
Registry number: EC 3.-
Synonym: cwlc gene product
(26 Jun 1999)
non-specific 1. Not due to any single known cause, as to a particular pathogen.
2. Not directed against a particular agent, but rather having a general effect, as non-specific therapy.
(18 Nov 1997)
non-specific anergy A reduction of the normal or usual immunologic responses because of unrelated intervening disease.
Synonym: non-specific anergy.
(05 Mar 2000)
non-specific cholinesterase <enzyme> An enzyme that breaks down acetylcholine tostop its action.
(22 May 1997)
non-specific protein A protein substance that elicits a response not mediated by specific antigen-antibody reaction.
(05 Mar 2000)
non-specific system <physiology> A physiological term denoting that part of the brainstem reticular formation that plays a central role in the organism's bodily and behavorial alertness.
It extends as a diffusely organised neural apparatus through the central region of the brainstem into the subthalamus and the intralaminar nuclei of the thalamus; by its ascending connections it affects the function of the cerebral cortex in the sense of behavioural responsiveness; its descending (reticulospinal) connections transmit its activating influence upon bodily posture and reflex mechanisms (e.g., muscle tonus), in part by way of the gamma motor neurons.
See: reticular formation.
Synonym: non-specific system.
(05 Mar 2000)
non-specific therapy The injection of a foreign protein, typhoid vaccine, etc., to induce fever in the treatment of certain diseases, especially those of a parasyphilitic nature.
Synonym: phlogotherapy.
(05 Mar 2000)
non-specific urethritis Urethritis not resulting from gonococcal, chlamydial, or other specific infectious agents.
Synonym: simple urethritis.
(05 Mar 2000)
non-specific vaginitis bacterial vaginosis
sugar-non-specific nuclease <enzyme> An exocytoplasmic sugar-non-specific nuclease that is able to degrade linear or covalently closed circular double-stranded DNA as well as single-stranded DNA or RNA; from cyanobacterium anabaena; mw 29 kD; amino acid sequence has been determined
Registry number: EC 3.1.-
Synonym: nuca gene product, anabaena
(26 Jun 1999)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á